Disclosing the cardiomyopathic substrate within the heart muscles in amyloidosis by cardiac magnetic resonance: diagnostic and prognostic implications

Abstract

The use of cardiac magnetic resonance (CMR) for accurate morphological assessment of cardiomyopathies is well described. CMR tissue characterization with late gadolinium enhancement and parametric mapping is highly promising in differentiating key etiologies of left ventricular hypertrophy, diagnosing cardiac involvement in systemic amyloidosis, detecting early disease, and tracking changes over time, as well as providing valuable prognostic information. This review focuses on the typical imaging findings in cardiac amyloidosis by CMR, highlighting its potentials with respect to traditional imaging techniques. Furthermore, the diagnostic and prognostic role of CMR parameters and the future perspectives related to the newest applications are addressed.

Keywords

Amyloidosis / cardiac magnetic resonance / tissue characterization / mapping

References

[1] Rapezzi C,Quarta CC.Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.Circulation2009;120:1203-12

[2] Kyle RA,Beard CM.Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.Blood1992;79:1817-22

[3] Brenner DA,Pimentel DR.Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress.Circ Res2004;94:1008-10

[4] González-López E,Guzzo-Merello G.Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.Eur Heart J2015;36:2585-94

[5] Bennani Smires Y,Ribes D.Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy.Int J Cardiovasc Imaging2016;32:1403-13

[6] Castaño A,Hamid N.Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.Eur Heart J2017;38:2879-87 PMCID:PMC5837725

[7] Ruberg FL.Transthyretin (TTR) cardiac amyloidosis.Circulation2012;126:1286-300 PMCID:PMC3501197

[8] Sipe JD,Buxbaum JN.Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines.Amyloid2016;23:209-13

[9] Pellikka PA., Edwards WD, et al. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement.Arch Intern Med1988;148:662-6.

[10] Dorbala S,Bokhari S.ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization.J Card Fail2019;25:854-65

[11] Gillmore JD,Falk RH.Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.Circulation2016;133:2404-12

[12] Hamer JP,van Rijswijk MH.Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis.Eur Heart J1992;13:623-7

[13] Quarta CC,Uraizee I.Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.Circulation2014;129:1840-9

[14] Phelan D,Thavendiranathan P.Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis.Heart2012;98:1442-8

[15] Williams LK,Popovic ZB.Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics.J Cardiovasc Magn Reson2017;19:61 PMCID:PMC5545847

[16] Löfbacka V,Pilebro B,Lindqvist P.Cardiac transthyretin amyloidosis ^99mTc-DPD SPECT correlates with strain echocardiography and biomarkers.Eur J Nucl Med Mol Imaging2021;48:1822-32 PMCID:PMC8113207

[17] Steen H,Montenbruck M.Left and right ventricular strain using fast strain-encoded cardiovascular magnetic resonance for the diagnostic classification of patients with chronic non-ischemic heart failure due to dilated, hypertrophic cardiomyopathy or cardiac amyloidosis.J Cardiovasc Magn Reson2021;23:45 PMCID:PMC8025329

[18] Giusca S,Montenbruck M.Multi-parametric assessment of left ventricular hypertrophy using late gadolinium enhancement, T1 mapping and strain-encoded cardiovascular magnetic resonance.J Cardiovasc Magn Reson2021;23:92 PMCID:PMC8273957

[19] Maceira AM,Prasad SK.Cardiovascular magnetic resonance in cardiac amyloidosis.Circulation2005;111:186-93

[20] Duca F,Panzenböck A.Cardiac magnetic resonance T₁ mapping in cardiac amyloidosis.JACC Cardiovasc Imaging2018;11:1924-6

[21] Burrage MK.Cardiovascular magnetic resonance for the differentiation of left ventricular hypertrophy.Curr Heart Fail Rep2020;17:192-204 PMCID:PMC7495998

[22] Fontana M,Reant P.Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis.Circulation2015;132:1570-9 PMCID:PMC4606985

[23] Zhao L,Fang Q.Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis.BMC Cardiovasc Disord2016;16:129 PMCID:PMC4897958

[24] Syed IS,Feng D.Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.JACC Cardiovasc Imaging2010;3:155-64

[25] Martinez-Naharro A,Abdel-Gadir A.Magnetic resonance in transthyretin cardiac amyloidosis.J Am Coll Cardiol2017;70:466-77

[26] Sado DM,Piechnik SK.Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping.Circ Cardiovasc Imaging2013;6:392-8

[27] Sado DM,Banypersad SM.Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease.Heart2012;98:1436-41

[28] Karamitsos TD,Banypersad SM.Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis.JACC Cardiovasc Imaging2013;6:488-97

[29] Fontana M,Treibel TA.Native T1 mapping in transthyretin amyloidosis.JACC Cardiovasc Imaging2014;7:157-65

[30] Baggiano A,Martinez-Naharro A.Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis.JACC Cardiovasc Imaging2020;13:69-80

[31] Banypersad SM,Flett AS.Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study.Circ Cardiovasc Imaging2013;6:34-9

[32] Martinez-Naharro A,Norrington K.Native T1 and extracellular volume in transthyretin amyloidosis.JACC Cardiovasc Imaging2019;12:810-9

[33] Pan JA,Salerno M.Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis.JACC Cardiovasc Imaging2020;13:1299-310 PMCID:PMC7340140

[34] Bandula S,Sado D.Measurement of Tissue interstitial volume in healthy patients and those with amyloidosis with equilibrium contrast-enhanced MR imaging.Radiology2013;268:858-64 PMCID:PMC6485500

[35] Fontana M,Treibel TA.AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect different biology.J Cardiovasc Magn Reson2014;16

[36] Fontana M,Treibel TA.Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study.Radiology2015;277:388-97

[37] Kotecha T,Treibel TA.Myocardial edema and prognosis in amyloidosis.J Am Coll Cardiol2018;71:2919-31

[38] Sharpley FA,Martinez-Naharro A.Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.Haematologica2020;105:1405-13 PMCID:PMC7193493

[39] Garcia-Pavia P,Adler Y.Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.Eur J Heart Fail2021;23:512-26

[40] Gertz MA,Falk RH.Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.Am J Hematol2005;79:319-28

[41] Grogan M,Kyle RA.Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system.J Am Coll Cardiol2016;68:1014-20

[42] Gillmore JD,Fontana M.A new staging system for cardiac transthyretin amyloidosis.Eur Heart J2018;39:2799-806

[43] Banypersad SM,Maestrini V.T1 mapping and survival in systemic light-chain amyloidosis.Eur Heart J2015;36:244-51 PMCID:PMC4301598

[44] Messroghli DR,Ferreira VM.Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI).J Cardiovasc Magn Reson2017;19:75 PMCID:PMC5633041

[45] Law S,Chacko L.Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage.ESC Heart Fail2020;7:3942-9 PMCID:PMC7755026

[46] Raina S,Nairooz RS.Prognostic value of late gadolinium enhancement CMR in systemic amyloidosis.JACC Cardiovasc Imaging2016;9:1267-77

[47] Boynton SJ,Dispenzieri A.LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis.JACC Cardiovasc Imaging2016;9:680-6

[48] Lin L,Feng J.The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis.J Cardiovasc Magn Reson2018;20:2 PMCID:PMC5753536

[49] Dorbala S,Bruyere J Jr.Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis.JACC Heart Fail2014;2:358-67 PMCID:PMC4127145

[50] Chacko L,Martinez-naharro A.1171Myocardial perfusion mapping in cardiac amyloidosis - exploring the spectrum from infiltration to ischaemia.Eur Heart J2019;40:ehz748.0013

[51] Palladini G,Merlini G.Management of AL amyloidosis in 2020.Blood2020;136:2620-7

[52] Addison D,Campbell CM,Jneid H.Recent advances and current dilemmas in the diagnosis and management of transthyretin cardiac amyloidosis.J Am Heart Assoc2021;10:e019840 PMCID:PMC8200718

[53] Martinez-Naharro A,Treibel TA.CMR-verified regression of cardiac AL amyloid after chemotherapy.JACC Cardiovasc Imaging2018;11:152-4

[54] Maurer MS,Gundapaneni B.ATTR-ACT Study InvestigatorsTafamidis treatment for patients with transthyretin amyloid cardiomyopathy.N Engl J Med2018;379:1007-16

[55] Solomon SD,Kristen A.Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis.Circulation2019;139:431-43

[56] Fontana M,Chacko L.Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression.JACC Cardiovasc Imaging2021;14:189-99